RxDoctor Payments Data

Unnikrishnan Ponnamma Kunjan Pillai, MD

Nephrology · Muncie, INNPI 1801086640

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (40.1%), consulting fees and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by GSK at 37.4% of the total. That places this record below the midpoint for nephrology clinicians in IN, where the typical reported total is $871.

$241in general payments, 2019–2025

Across 11 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$90
  • Boehringer Ingelheim$39
  • Daiichi Sankyo Inc.$28
  • Bayer$20
  • Otsuka America Pharmaceutical, Inc.$19
  • Fresenius USA Marketing, Inc.$15
  • plus $30 from 3 others
$67,856in research payments, 2019–2025

Across 77 payments — averaging $881.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Akebia Therapeutics Inc$68K

What the payments were for

  • Consulting fees$9037%
  • Food & beverage$9740%
  • Education$5423%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$241 in reported general payments places this provider in the 30th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$176,008
Medicare patients
346
Services billed
1,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin96$126,808
FarxigaDapagliflozin Propanediol109$102,389
LokelmaSodium Zirconium Cyclosilicate52$61,377
VelphoroSucroferric Oxyhydroxide12$31,746
KerendiaFinerenone21$17,717
ProsolParenteral Amino Acid 20% No.163$10,300
ClinolipidFat Emulsion/Olive/Soy/Phospho36$9,028
Sevelamer Carbonate78$7,548
Chlorthalidone150$2,684
Torsemide124$1,925
Mycophenolate Mofetil12$1,901
Calcitriol175$1,444
Potassium Chloride55$1,303
Losartan Potassium144$940
Amlodipine Besylate152$734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$15$163,767161 claims
Boehringer IngelheimJardiance$39$126,80896 claims
Fresenius USA Marketing, Inc.Velphoro$15$31,74612 claims
BayerKerendia$20$17,71721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 238 nephrology providers in Indiana.

Other nephrology in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →